Your browser doesn't support javascript.
loading
Mechanisms of obesity-induced metabolic and vascular dysfunctions.
Atawia, Reem T; Bunch, Katharine L; Toque, Haroldo A; Caldwell, Ruth B; Caldwell, Robert W.
Afiliación
  • Atawia RT; Department of Pharmacology and Toxicology, Medical College of Georgia, Augusta University. Augusta, GA 30904, USA.
  • Bunch KL; Department of Pharmacology and Toxicology, Medical College of Georgia, Augusta University. Augusta, GA 30904, USA.
  • Toque HA; Department of Pharmacology and Toxicology,and Vascular Biology Center, Medical College of Georgia, Augusta University. Augusta, GA 30904, USA.
  • Caldwell RB; Vascular Biology Center, Medical College of Georgia, Augusta University. Augusta, GA 30904, USA.
  • Caldwell RW; Vascular Biology Center, Medical College of Georgia, Augusta University. Augusta, GA 30904,USA, wcaldwel@augusta.edu.
Front Biosci (Landmark Ed) ; 24(5): 890-934, 2019 03 01.
Article en En | MEDLINE | ID: mdl-30844720
Obesity has reached epidemic proportions and its prevalence is climbing. Obesity is characterized by hypertrophied adipocytes with a dysregulated adipokine secretion profile, increased recruitment of inflammatory cells, and impaired metabolic homeostasis that eventually results in the development of systemic insulin resistance, a phenotype of type 2 diabetes. Nitric oxide synthase (NOS) is an enzyme that converts L-arginine to nitric oxide (NO), which functions to maintain vascular and adipocyte homeostasis. Arginase is a ureohydrolase enzyme that competes with NOS for L-arginine. Arginase activity/expression is upregulated in obesity, which results in diminished bioavailability of NO, impairing both adipocyte and vascular endothelial cell function. Given the emerging role of NO in the regulation of adipocyte physiology and metabolic capacity, this review explores the interplay between arginase and NO, and their effect on the development of metabolic disorders, cardiovascular diseases, and mitochondrial dysfunction in obesity. A comprehensive understanding of the mechanisms involved in the development of obesity-induced metabolic and vascular dysfunction is necessary for the identification of more effective and tailored therapeutic avenues for their prevention and treatment.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Arginasa / Enfermedades Vasculares / Enfermedades Metabólicas / Óxido Nítrico / Obesidad Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Animals / Humans Idioma: En Revista: Front Biosci (Landmark Ed) Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Singapur

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Arginasa / Enfermedades Vasculares / Enfermedades Metabólicas / Óxido Nítrico / Obesidad Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Animals / Humans Idioma: En Revista: Front Biosci (Landmark Ed) Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Singapur